PriZm Therapeutics
1 known investors
PriZm Tx develops treatments for ultra-rare genetic disorders, including a first-in-class treatment (SRW101) for MCT8 deficiency (AHDS). The company focuses on advancing therapeutics to improve human health and well-being.
BiotechHealthtechMedical Devices